Published in Immunity on July 01, 1998
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med (2003) 2.48
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 1.65
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci U S A (2000) 1.57
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization. J Mol Cell Cardiol (2014) 1.48
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med (2003) 1.44
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest (2001) 1.30
Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol (2012) 1.27
Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology (2015) 1.16
CD4 T cells in tumor immunity. Springer Semin Immunopathol (2005) 1.13
Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer (2003) 1.07
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol (2012) 0.97
Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology (2002) 0.94
High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother (2009) 0.91
Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol (2011) 0.91
CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology (2007) 0.90
Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol (2004) 0.90
IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol (2010) 0.88
CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. Cancer Res (2011) 0.88
Biologic functions of the IFN-gamma receptors. Allergy (1999) 0.87
Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma. Int J Cancer (2004) 0.86
Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol (2001) 0.86
Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One (2014) 0.85
Phorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line. Cancer Cell Int (2003) 0.84
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Interleukin-19 can enhance angiogenesis by Macrophage Polarization. Macrophage (Houst) (2015) 0.79
Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis (2010) 0.79
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy. BMC Cancer (2016) 0.76
Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma. Cell Mol Immunol (2004) 0.75
CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control. Oncoimmunology (2016) 0.75
Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent. BMC Vet Res (2015) 0.75
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature (2017) 0.75
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. Cell Rep (2015) 0.75
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun (2017) 0.75
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med (1993) 8.76
Interferons and their actions. Annu Rev Biochem (1987) 8.36
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol (2001) 8.31
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med (1993) 8.03
Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol (1999) 7.72
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol (1995) 6.09
Human leukocyte interferon produced by E. coli is biologically active. Nature (1980) 5.86
Inhibitors of ribosome functions. Annu Rev Microbiol (1971) 5.56
Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med (1984) 5.26
Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol (1983) 4.94
Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol (1994) 4.86
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell (2001) 4.73
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med (1987) 4.54
The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science (1994) 4.38
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
Acetaminophen toxicity in an urban county hospital. N Engl J Med (1997) 4.26
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol (2001) 3.86
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med (1996) 3.82
Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol (1995) 3.76
Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res (1980) 3.75
Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron (2000) 3.73
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
Mechanism of suppression of cell-mediated immunity by measles virus. Science (1996) 3.55
CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 3.52
Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul (1987) 3.45
CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol (1999) 3.32
Identification of the human c-myc protein nuclear translocation signal. Mol Cell Biol (1988) 3.30
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet (2000) 3.25
Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol (1996) 3.24
Fas-induced caspase denitrosylation. Science (1999) 3.21
Dimensions of child maltreatment and children's adjustment: contributions of developmental timing and subtype. Dev Psychopathol (2001) 3.16
Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol (1992) 3.15
Differential regulation of circadian pacemaker output by separate clock genes in Drosophila. Proc Natl Acad Sci U S A (2000) 3.11
Human natural killer cells: biologic and pathologic aspects. Lab Invest (1984) 2.99
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity (1998) 2.95
Convenient assay for interferons. J Virol (1981) 2.95
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature (1997) 2.94
Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med (1983) 2.93
Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. J Biol Chem (1989) 2.89
Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88
STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med (1997) 2.86
B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med (1994) 2.85
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Central melanocortin receptors regulate insulin action. J Clin Invest (2001) 2.83
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A (2000) 2.83
Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med (1994) 2.82
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med (1988) 2.79
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Critical residues for histone acetylation by Gcn5, functioning in Ada and SAGA complexes, are also required for transcriptional function in vivo. Genes Dev (1998) 2.76
IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol (1995) 2.72
Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. Nature (1989) 2.70
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol (1984) 2.70
c-myc gene expression is stimulated by agents that activate protein kinase C and does not account for the mitogenic effect of PDGF. Cell (1985) 2.69
Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod (2008) 2.68
The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci U S A (1996) 2.68
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem (2001) 2.67
Human Mig chemokine: biochemical and functional characterization. J Exp Med (1995) 2.67
Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 2.65
The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem (1999) 2.64
Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry (1998) 2.62
The practice of neurology, 2000-2010: report of the AAN Member Research Subcommittee. Neurology (2011) 2.59
Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med (2001) 2.55
Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med (1995) 2.55
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 2.55
Clinical manifestations and diagnosis of acute pyrethroid poisoning. Arch Toxicol (1989) 2.50
Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem (1982) 2.49
Fungal infections in patients with acute leukemia. Am J Med (1982) 2.43
Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med (2000) 2.40
Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med (1999) 2.39
Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol (2001) 2.38
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J Immunol (1983) 2.37